IP Library › Granted Patent US 6,894,155
Granted Patent B2
US 6,894,155 · App. 09/976,605 · Granted May 17, 2005

Nucleic acid molecules and polypeptides for immune modulation

Assignee: Viron Therapeutics
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,894,155
App. No.
09/976,605
Granted
May 17, 2005
Kind
B2
Abstract

The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.

Claims (15)

1. A substantially pure Yatapoxvirus nucleic acid molecule having at least 99% nucleic acid sequence identity to SEQ ID NO:5, wherein said nucleic acid molecule encodes a polypeptide that decreases T cell stimulation or inflammation.

2. The nucleic acid molecule of claim 1 , wherein said nucleic acid molecule is selected from the group consisting of genomic DNA, cDNA, and mRNA.

3. The nucleic acid molecule of claim 1 , wherein said nucleic acid molecule comprises a nucleotide sequence that encodes a polypeptide with an identifiable signal sequence.

4. The nucleic aeid molecule of claim 1 , wherein said nucleic acid molecule encodes a tanapox virus polypeptide.

5. The nucleic acid molecule of claim 1 , wherein said nucleic acid molecule encodes a polypeptide comprising an amino acid sequence that is 99% identical to the amino acid sequence SEQ ID NO: 4.

6. The nucleic acid molecule of claim 5 , wherein said nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 4.

7. A vector comprising the nucleic acid molecule of claim 1 .

8. The vector of claim 7 , wherein said vector is a mammalian expression vector.

9. A cell comprising the vector of claim 7 .

10. The vector of claim 7 , wherein said nucleic acid molecule is operably linked to regulatory sequences for expression of a tanapox virus polypeptide and wherein said regulatory sequences comprise a promoter.

11. The cell of claim 9 , wherein said cell is selected from the group consisting of a human cell, a primate cell, and a rodent cell.

12. An isolated nucleic acid molecule comprising SEQ ID NO:5.

13. An isolated nucleic acid molecule that consists of SEQ ID NO:5.

14. An isolated nucleic acid molecule comprising a sequence encoding SEQ ID NO:4.

15. An isolated nucleic acid molecule consisting of a sequence that encodes SEQ ID NO:4.

Assignments (9)
SECURITY AGREEMENT Recorded Jul 8, 2008
From: EASTERN TECHNOLOGY SEED INVESTMENT FUND LIMITED PARTNERSHIP; TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG; ROYAL BANK OF CANADAD; GENECHEM TECHNOLOGIES VENTURE FUND, L.P.
To: VIRON THERAPEUTICS INC.
Reel/Frame 021205/0109 →
SECURITY AGREEMENT Recorded Jul 8, 2008
From: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG; ROYAL BANK OF CANADAD; GENECHEM TECHNOLOGIES VENTURE FUND, L.P.
To: VIRON THERAPEUTICS INC.
Reel/Frame 021205/0124 →
SECURITY AGREEMENT Recorded Jul 8, 2008
From: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG
To: VIRON THERAPEUTICS INC.
Reel/Frame 021205/0135 →
SECURITY AGREEMENT Recorded Jul 8, 2008
From: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG
To: VIRON THERAPEUTICS INC.
Reel/Frame 021205/0143 →
SECURITY AGREEMENT Recorded Jul 12, 2004
From: VIRON THERAPEUTICS INC.
To: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG
Reel/Frame 016256/0117 →
SECURITY INTEREST Recorded Dec 9, 2003
From: VIRON THERAPEUTICS INC.
To: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG
Reel/Frame 014754/0221 →
SECURITY INTEREST Recorded Dec 9, 2003
From: VIRON THERAPEUTICS INC.
To: TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG (AS ASSIGNEE OF NOVARTIS INTERNATIONAL AG); ROYAL BANK OF CANADA; GENECHEM TECHNOLOGIES VENTURE FUND, L.P.
Reel/Frame 014754/0266 →
SECURITY INTEREST Recorded Dec 8, 2003
From: VIRON THERAPEUTICS INC.
To: EASTERN TECHNOLOGY SEED INVESTMENT FUND LIMITED PARTNERSHIP; TRUDELL MEDICAL LIMITED; NOVARTIS PHARMA AG (AS ASSIGNEE OF NOVARTIS INTERNATIONAL AG); ROYAL BANK OF CANADA; GENECHEM TECHNOLOGIES VENTURE FUND, L.P.
Reel/Frame 014754/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2002
From: MCFADDEN, GRANT; ESSANI, KARIM
To: VIRON THERAPEUTICS
Reel/Frame 012643/0742 →
Continuity (2)
Provisional Application 6023935400 · Oct 11, 2000
Related Publication 20020102535A1 · Aug 1, 2002